Spectrum of mast cell activation disorders

References

• Chen CC, Grimbaldeston MA, Tsai M, et al. Identification of mast cell progenitors in adult mice. Proc Natl Acad Sci USA 2005;102(32):11408-13
   Google Scholar
• Theoharides TC, Alysandratos KD, Angelidou A, et al. Mast cells and inflammation. Biochim Biophys Acta 2010;1822(1):21-33
   Google Scholar
• Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 2008;8(6):478-86
   PubMed Web of Science ®Google Scholar
• Sismanopoulos N, Delivanis DA, Alysandratos KD, et al. Mast cells in allergic and inflammatory diseases. Curr Pharm Des 2012;18(16):2261-77
   Google Scholar
• Picard M, Giavina-Bianchi P, Mezzano V, Castells M. Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes. Clin Ther 2013;35(5):548-62
   Google Scholar
• Theoharides TC, Bondy PK, Tsakalos ND, Askenase PW. Differential release of serotonin and histamine from mast cells. Nature 1982;297:229-31
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 2004;146(1-2):1-12
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Kempuraj D, Tagen M, et al. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 2007;217:65-78
   PubMed Web of Science ®Google Scholar
• Zhang B, Asadi S, Weng Z, et al. Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions. PLoS One 2012;7(12):e49767
   PubMed Web of Science ®Google Scholar
• Zhang B, Alysandratos KD, Angelidou A, et al. Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis. J Allergy Clin Immunol 2011;127(6):1522-31
   Google Scholar
• Nakae S, Suto H, Kakurai M, et al. Mast cells enhance T cell activation: importance of mast cell-derived TNF. Proc Natl Acad Sci USA 2005;102(18):6467-72
   Google Scholar
• Kempuraj D, Tagen M, Iliopoulou BP, et al. Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell dependent stimulation of Jurkat T cells. Br J Pharmacol 2008;155(7):1076-84
   PubMed Web of Science ®Google Scholar
• Zhang B, Weng Z, Sismanopoulos N, et al. Mitochondria distinguish granule-stored from de novo synthesized tumor necrosis factor secretion in human mast cells. Int Arch Allergy Immunol 2012;159(1):23-32
   Google Scholar
• Askenase PW. Mast cells and the mediation of T-cell recruitment in arthritise. N Engl J Med 2005;349:1294
   Web of Science ®Google Scholar
• Salamon P, Shoham NG, Gavrieli R, et al. Human mast cells release interleukin-8 and induce neutrophil chemotaxis on contact with activated T cells. Allergy 2005;60(10):1316-19
   Google Scholar
• Sismanopoulos N, Delivanis DA, Mavrommati D, et al. Do mast cells link obesity and asthma? Allergy 2013;68(1):8-15
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Asadi S, Panagiotidou S, Weng Z. The “missing link” in autoimmunity and autism: extracellular mitochondrial components secreted from activated live mast cells. Autoimmun Rev 2013;12(12):1136-42
   Google Scholar
• Theoharides TC, Sismanopoulos N, Delivanis DA, et al. Mast cells squeeze the heart and stretch the gird: their role in atherosclerosis and obesity. Trends Pharmacol Sci 2011;32(9):534-42
   PubMed Web of Science ®Google Scholar
• Alevizos M, Karagkouni A, Panagiotidou S, et al. Stress triggers coronary mast cells leading to cardiac events. Ann Allergy Asthma Immunol 2013. [Epub ahead of print]
   Google Scholar
• Metcalfe DD, Schwartz LB. Assessing anaphylactic risk? Consider mast cell clonality. J Allergy Clin Immunol 2009;123(3):687-8
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Zhang B, Kempuraj D, et al. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci USA 2010;107(9):4448-53
   PubMed Web of Science ®Google Scholar
• Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009;123(3):680-6
   PubMed Web of Science ®Google Scholar
• Niedoszytko M, de MJ, van Doormaal JJ, et al. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009;64(9):1237-45
   PubMedGoogle Scholar
• Bonadonna P, Zanotti R, Muller U. Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol 2010;10(4):347-53
   Google Scholar
• Wimazal F, Geissler P, Shnawa P, et al. Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience. Int Arch Allergy Immunology 2012;417-24
   Google Scholar
• Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010;126(3):477-80
   PubMed Web of Science ®Google Scholar
• Kritas SK, Saggini A, Varvara G, et al. Mast cell involvement in rheumatoid arthritis. J Biol Regul Homeost Agents 2013;27(3):655-60
   PubMedGoogle Scholar
• Schwartz LB. Mast cells and basophils. Clin Allergy Immunol 2002;16:3-42
   PubMedGoogle Scholar
• Gibbs BF. Human basophils as effectors and immunomodulators of allergic inflammation and innate immunity. Clin Exp Med 2005;5(2):43-9
   PubMed Web of Science ®Google Scholar
• Hauswirth AW, Natter S, Ghannadan M, et al. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol 2002;110(1):102-9
   Google Scholar
• Valent P, Hauswirth AW, Natter S, et al. Assays for measuring in vitro basophil activation induced by recombinant allergens. Methods 2004;32(3):265-70
   Google Scholar
• Hauswirth AW, Escribano L, Prados A, et al. CD203c is overexpressed on neoplastic mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking. Int J Immunopathol Pharmacol 2008;21(4):797-806
   Google Scholar
• Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol 2010;126(6):1099-104
   PubMed Web of Science ®Google Scholar
• Molderings GJ, Haenisch B, Bogdanow M, et al. Familial occurrence of systemic mast cell activation disease. PLoS One 2013;8(9):e76241
   Google Scholar
• Samorapoompichit P, Kiener HP, Schernthaner GH, et al. Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. Blood 2001;98(8):2580-3
   PubMed Web of Science ®Google Scholar
• Jogie-Brahim S, Min HK, Fukuoka Y, et al. Expression of alpha-tryptase and beta-tryptase by human basophils. J Allergy Clin Immunol 2004;113(6):1086-92
   PubMed Web of Science ®Google Scholar
• Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012;157(3):215-25
   PubMed Web of Science ®Google Scholar
• Shanmugam G, Schwartz LB, Khan DA. Prolonged elevation of serum tryptase in idiopathic anaphylaxis. J Allergy Clin Immunol 2006;117(4):950-1
   Google Scholar
• Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006;26(3):451-63
   PubMed Web of Science ®Google Scholar
• Lin RY, Schwartz LB, Curry A, et al. Histamine and tryptase levels in patients with acute allergic reactions: an emergency department-based study. J Allergy Clin Immunol 2000;106(1 Pt 1):65-71
   PubMed Web of Science ®Google Scholar
• Oosting E, Neugebauer E, Keyzer JJ, Lorenz W. Determination of histamine in human plasma: the European external quality control study 1988. Clin Exp Allergy 1990;20(4):349-57
   Google Scholar
• Awad JA, Morrow JD, Roberts LJ. Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation. J Allergy Clin Immunol 1994;93(5):817-24
   Google Scholar
• Theoharides TC, Boucher W, Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 2002;128:344-50
   PubMed Web of Science ®Google Scholar
• Brockow K, Akin C, Huber M, Metcalfe DD. IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 2005;115(2):216-23
   PubMed Web of Science ®Google Scholar
• Horny HP, Sotlar K, Valent P. Evaluation of mast cell activation syndromes: impact of pathology and immunohistology. Int Arch Allergy Immunol 2012;159(1):1-5
   Google Scholar
• Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37(6):435-53
   PubMed Web of Science ®Google Scholar
• Theoharidess T.C. Irritable Bowel Syndrome and Ulcerative Colitis: mast Cell Numbers are Increased, but Activation is more important. Dig Dis Sci 2014; In press
   Google Scholar
• Lindner PS, Pardanani B, Angadi C, Frieri M. Acute nonlymphocytic leukemia in systemic mastocytosis with biclonal gammopathy. J Allergy Clin Immunol 1992;90(3 Pt 1):410-12
   Google Scholar
• Sonneck K, Florian S, Mullauer L, et al. Diagnostic and Subdiagnostic Accumulation of Mast Cells in the Bone Marrow of Patients with Anaphylaxis: monoclonal Mast Cell Activation Syndrome. Int Arch Allergy Immunol 2006;142(2):158-64
   Google Scholar
• Alvarez-Twose I, Zanotti R, Gonzalez-de-Olano D, et al. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol 2014;133(2):520-8; e5
   PubMed Web of Science ®Google Scholar
• Wang SA, Hutchinson L, Tang G, et al. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol 2013;88(3):219-24
   PubMed Web of Science ®Google Scholar
• Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92:1736-44
   PubMed Web of Science ®Google Scholar
• Gagari E, Tsai M, Lantz CS, et al. Differential release of mast cell interleukin-6 via c-kit. Blood 1997;89(8):2654-63
   Google Scholar
• Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood 2007;110(7):2331-3
   PubMed Web of Science ®Google Scholar
• Hamilton MJ, Hornick JL, Akin C, et al. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol 2011;128(1):147-52
   Google Scholar
• Valent P, Horny HP, Triggiani M, Arock M. Clinical and laboratory parameters of mast cell activation as basis for the formulation of diagnostic criteria. Int Arch Allergy Immunol 2011;156(2):119-27
   Google Scholar
• Alvarez-Twose I, Vano-Galvan S, Sanchez-Munoz L, et al. Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis. Allergy 2012;67(6):813-21
   Google Scholar
• Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004;104(10):3038-45
   Google Scholar
• Castells M, Metcalfe DD, Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol 2011;12(4):259-70
   Google Scholar
• Cardet JC, Castells MC, Hamilton MJ. Immunology and clinical manifestations of non-clonal mast cell activation syndrome. Curr Allergy Asthma Rep 2013;13(1):10-18
   Google Scholar
• Theoharides TC, Kempuraj D, Marchand J, et al. Urticaria pigmentosa associated with acute stress and lesional skin mast cell expression of CRF-R1. Clin Exp Dermatol 2008;34(5):e163-6
   Google Scholar
• Cao J, Papadopoulou N, Kempuraj D, et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 2005;174(12):7665-75
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Donelan JM, Papadopoulou N, et al. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci 2004;25(11):563-8
   Google Scholar
• Worobec AS, Semere T, Nagata H, Metcalfe DD. Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer 1998;83(10):2120-9
   Google Scholar
• Mousli M, Bueb J-L, Bronner C, et al. G protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides. Trends Pharmacol Sci 1990;11:358-62
   PubMed Web of Science ®Google Scholar
• Woolhiser MR, Brockow K, Metcalfe DD. Activation of human mast cells by aggregated IgG through FcγRI: additive effects of C3a. Clin Immunol 2004;110:172-80
   PubMed Web of Science ®Google Scholar
• Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr 2007;85(5):1185-96
   PubMed Web of Science ®Google Scholar
• Lucas HJ, Brauch CM, Settas L, Theoharides TC. Fibromyalgia--new concepts of pathogenesis and treatment. Int J Immunopathol Pharmacol 2006;19(1):5-10
   PubMed Web of Science ®Google Scholar
• Blanco I, Beritze N, Arguelles M, et al. Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients. Clin Rheumatol 2010;29(12):1403-12
   PubMed Web of Science ®Google Scholar
• Theoharides TC. Atopic conditions in search of pathogenesis and therapy. Clin Ther 2013;35(5):544-7
   PubMed Web of Science ®Google Scholar
• Alvarez-Twose I, Gonzalez-de-Olano D, Sanchez-Munoz L, et al. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. Int Arch Allergy Immunol 2012;157(3):275-80
   PubMed Web of Science ®Google Scholar
• Kettelhut BV, Berkebile C, Bradley D, Metcalfe DD. A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis. J Allergy Clin Immunol 1989;83(5):866-70
   Google Scholar
• Schoch C. In vitro inhibition of human conjunctival mast-cell degranulation by ketotifen. J Ocul Pharmacol Ther 2003;19(1):75-81
   PubMed Web of Science ®Google Scholar
• Vasiadi M, Kalogeromitros K, Kempuraj D, et al. Rupatadine inhibits pro-inflammatory mediator secretion from human mast cells triggered by different stimuli. Int Arch Allergy Immunol 2010;151(1):38-45
   PubMed Web of Science ®Google Scholar
• Oka T, Kalesnikoff J, Starkl P, et al. Evidence questioning cromolyn’s effectiveness and selectivity as a ‘mast cell stabilizer’ in mice. Lab Invest 2012;92(10):1472-82
   PubMed Web of Science ®Google Scholar
• Vieira Dos SR, Magerl M, Martus P, et al. Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. Br J Dermatol 2010;162(3):674-6
   Google Scholar
• Castells M, Metcalfe DD, Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol 2011;12(4):259-70
   Google Scholar
• Butterfield JH, Weiler CR. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production. Int Arch Allergy Immunol 2008;147(4):338-43
   Google Scholar
• Conti P, Varvara G, Murmura G, et al. Comparison of beneficial actions of non-steroidal anti-inflammatory drugs to flavonoids. J Biol Regul Homeost Agents 2013;27(1):1-7
   Google Scholar
• Butterfield JH, Kao PC, Klee GC, Yocum MW. Aspirin idiosyncrasy in systemic mast cell disease: a new look at mediator release during aspirin desensitization. Mayo Clin Proc 1995;70(5):481-7
   Google Scholar
• Jayapal M, Tay HK, Reghunathan R, et al. Genome-wide gene expression profiling of human mast cells stimulated by IgE or FcepsilonRI-aggregation reveals a complex network of genes involved in inflammatory responses. BMC Genomics 2006;7:210
   PubMed Web of Science ®Google Scholar
• Molderings GJ, Raithel M, Kratz F, et al. Omalizumab treatment of systemic mast cell activation disease: experiences from four cases. Intern Med 2011;50(6):611-15
   Google Scholar
• Kalogeromitros D, Makris M, Koti I, et al. A simple 3-day "rush" venom immunotherapy protocol: documentation of safety. Allergol Immunopathol (Madr) 2010;38(2):69-73
   Google Scholar
• Middleton EJ, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol Rev 2000;52(4):673-751
   PubMed Web of Science ®Google Scholar
• Kimata M, Shichijo M, Miura T, et al. Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy 2000;30(4):501-8
   Web of Science ®Google Scholar
• Asadi S, Theoharides TC. Corticotropin-releasing hormone and extracellular mitochondria augment IgE-stimulated human mast-cell vascular endothelial growth factor release, which is inhibited by luteolin. J Neuroinflammation 2012;9(1):85
   Google Scholar
• Dirscherl K, Karlstetter M, Ebert S, et al. Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype. J Neuroinflammation 2010;7(1):3
   Google Scholar
• Jang S, Dilger RN, Johnson RW. Luteolin inhibits microglia and alters hippocampal-dependent spatial working memory in aged mice. J Nutr 2010;140(10):1892-8
   PubMed Web of Science ®Google Scholar
• Verbeek R, Plomp AC, van Tol EA, van Noort JM. The flavones luteolin and apigenin inhibit in vitro antigen-specific proliferation and interferon-gamma production by murine and human autoimmune T cells. Biochem Pharmacol 2004;68(4):621-9
   PubMed Web of Science ®Google Scholar
• Chen HQ, Jin ZY, Wang XJ, et al. Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation. Neurosci Lett 2008;448(2):175-9
   PubMed Web of Science ®Google Scholar
• Jang SW, Liu X, Yepes M, et al. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci USA 2010;107(6):2687-92
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Asadi S, Panagiotidou S. A case series of a luteolin formulation (Neuroprotek®) in children with autism spectrum disorders. Int J Immunopathol Pharmacol 2012;25(2):317-23
   PubMed Web of Science ®Google Scholar
• Taliou A, Zintzaras E, Lykouras L, Francis K. An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clin Ther 2013;35(5):592-602
   PubMed Web of Science ®Google Scholar
• Harwood M, Nielewska-Nikiel B, Borzelleca JF, et al. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 2007;45(11):2179-205
   PubMed Web of Science ®Google Scholar
• Domitrovic R, Jakovac H, Milin C, Radosevic-Stasic B. Dose- and time-dependent effects of luteolin on carbon tetrachloride-induced hepatotoxicity in mice. Exp Toxicol Pathol 2009;61(6):581-9
   Google Scholar
• Butterfield JH, Li CY. Bone marrow biopsies for the diagnosis of systemic mastocytosis: is one biopsy sufficient? Am J Clin Pathol 2004;121(2):264-7
   Google Scholar